(RTTNews) - MannKind (MNKD) announced that the FDA has approved an update to the Prescribing Information for Afrezza Inhalation Powder, revising recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. The updated labeling was supported by modeling data and in vivo results from the Dose Optimization study and the INHALE-3 trial.
"We expect that this label update will help support healthcare providers by providing clearer starting dose guidance when transitioning patients to inhaled insulin from subcutaneous mealtime insulinwhether injections or insulin pumps," said Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Diabetes at MannKind.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
